Honest Criticisms and Limitations of the STEP-3 Trial
A deep-dive into the enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest issues in the STEP-3 semaglutide 2.4 mg + intensive behavioral therapy trial.
Trials Step 3
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
8articles
3topic areas covered
May 25, 2026latest review
Trials Step 3 library
Showing 8 of 8 clinical reviews.
Inside the STEP-3 Methodology: What Most Summaries Skip
A detailed methodology breakdown of the STEP-3 trial (semaglutide 2.4 mg + intensive behavioral therapy), covering randomization, blinding, estimand framework, inclusion criteria, and how each design choice shapes clinical interpretation.
STEP-3 Cost, Cost-Effectiveness, and Health-Economic Implications
Health-economic analysis of semaglutide 2.4 mg plus intensive behavioral therapy from the STEP-3 trial: cost per QALY, payer coverage trends, list-price vs net-price realities, and individual value calculations.
STEP-3 Extension Data and What Happened After the Trial Ended
Deep-dive into STEP-3 follow-up and extension findings for semaglutide 2.4 mg plus intensive behavioral therapy, covering weight regain after discontinuation, durability signals, and long-term safety.
STEP-3 Results in Detail: Numbers, Subgroups, and Time Course
Complete breakdown of the STEP-3 trial's primary and secondary endpoints for semaglutide 2.4 mg plus intensive behavioral therapy, including effect sizes, confidence intervals, response distribution, and time-course data.
STEP-3 Subgroup Analyses: Who Responded Most and Least
Deep dive into STEP-3 pre-specified and post-hoc subgroup analyses for semaglutide 2.4 mg plus intensive behavioral therapy, examining differential responses by age, sex, BMI, race, and baseline cardiometabolic markers.
STEP-3 Trial: A Plain-English Overview of What It Established
A deep-dive overview of the STEP-3 trial (2021): semaglutide 2.4 mg combined with intensive behavioral therapy produced 16.0% weight loss vs 5.7% with placebo plus IBT at 68 weeks in adults with overweight or obesity.
What STEP-3 Actually Changes in Clinical Practice
How the STEP-3 trial of semaglutide 2.4 mg plus intensive behavioral therapy reshapes prescribing decisions, guideline recommendations, and real-world obesity management protocols.